TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07524348: A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Sponsor: Samsung Bioepis Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 149 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07524348 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07524348 Rescue Dossier →